SHINE announces that it has completed its acquisition of Lantheus’ SPECT business, including the North Billerica, Massachusetts SPECT manufacturing facility and its portfolio of diagnostic radiopharmaceuticals. The acquisition brings immediate revenue and operational scale in the $19 billion nuclear medicine market. The SPECT facility has manufactured TechneLite® (Technetium Tc 99m Generator) for 55 years, serving hospitals and imaging centers across North America. The product portfolio also includes SPECT imaging agents Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) and NEUROLITE® (Kit for the Preparation of Technetium Tc99m Bicisate for Injection), as well as Xenon Xe-133 Gas for pulmonary imaging.
Read the full article: SHINE Completes Acquisition of Lantheus SPECT Business //
Source: https://www.prnewswire.com/news-releases/shine-completes-acquisition-of-lantheus-spect-business-names-michael-rossi-shine-spect-ceo-302651561.html